Showing results (1-10 of 18) with videos related to

Sort By:
Pageof 2
Joint Bone Spine|November 1, 2020
The role of interleukin-1 family members in hyperuricemia and goutViola Klück, Ruiqi Liu, Leo A B Joosten
Frontiers in Endocrinology|March 6, 2015
Autophagy in thyroid cancer: present knowledge and future perspectivesRomana T Netea-Maier, Viola Klück, Theo S Plantinga, et al.
Immunological Reviews|December 20, 2019
Urate-induced immune programming: Consequences for gouty arthritis and hyperuricemiaGeorgiana Cabău, Tania O Crișan, Viola Klück, et al.
Cytokine|January 18, 2024
Soluble urate-induced effects on cytokine production in vitro - Assessment of methodologies and cell typesRuiqi Liu, Viola Klück, Brenda Kischkel, et al.
Arthritis Research & Therapy|February 28, 2023
TGF-β is elevated in hyperuricemic individuals and mediates urate-induced hyperinflammatory phenotype in human mononuclear cellsViola Klück, Georgiana Cabău, Linda Mies, et al.
Cytokine|December 8, 2022
Effect of exogenous IL-37 on immune cells from a patient carrying a potential IL37 loss-of-function variant: A case studyLisa U Teufel, Caspar I van der Made, Viola Klück, et al.
Immunology|October 2, 2024
Downregulation of type I interferon signalling pathway by urate in primary human PBMCsMedeea Badii, Valentin Nica, Ancuța R Straton, et al.
The Journal of Biological Chemistry|July 15, 2018
Interleukin-37 treatment of mice with metabolic syndrome improves insulin sensitivity and reduces pro-inflammatory cytokine production in adipose tissueDov B Ballak, Suzhao Li, Giulio Cavalli, et al.
The Lancet. Rheumatology|October 2, 2020
Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trialViola Klück, Tim L Th A Jansen, Matthijs Janssen, et al.
Iscience|March 21, 2024
Epigenetic, transcriptional, and functional characterization of myeloid cells in familial Mediterranean feverRutger J Röring, Wenchao Li, Ruiqi Liu, et al.
Pageof 2